Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Wanda Launches First Consumer App

19 Aug 2016 07:00

RNS Number : 6055H
NetScientific PLC
19 August 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

 

myWanda Mobile App Launches to Help Women

Manage Heart Health with Personalized Guidance

 

myWanda is Wanda's first consumer app, making it easier for women to receive support, education and guidance on heart health

 

London, UK - 19 August 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, announces that its digital health portfolio company, Wanda has launched myWanda, the first and only mobile application aimed at empowering women to improve the health of their hearts.

 

Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, said: "The myWanda mobile app now available on the US iTunes App Store will serve to deliver personalized support for developing healthy behaviours and ensure patients are increasingly at the heart of the care process. This is an important milestone for Wanda, and is line with the Company's strategy to expand its platform of mobile applications to capture patients earlier in their disease trajectory."

 

The full text of the announcement issued by Wanda on 18th August 2016 is as follows:

 

 

myWanda Mobile App Launches to Help Women Manage Heart Health With Personalized Guidance

 

myWanda Acts as a Personal Companion, Motivator, and Educator for Women to Enable Them to Manage Their Heart Health

 

SAN FRANCISCO, CA--(Marketwired - Aug 18, 2016) - Wanda (http://yourwanda.com/), a leading digital health platform dedicated to advancing the effectiveness and efficiency of chronic health condition management, today announced the launch of myWanda, the first and only mobile application specifically aimed at empowering women to improve the health of their hearts.

Wanda is expanding its analytics ecosystem with mobile applications to engage individuals earlier in their lives, onboarding them onto the Wanda platform. myWanda will also add considerably to the richness of Wanda's data and machine-learning engine, enabling the Company to advance upcoming product applications and features.

 

Available today in the iTunes App Store, myWanda delivers personalized support for developing heart healthy behaviors. The app encourages women to set specific lifestyle goals known as "Pathways" for exercise, nutrition, sleep, stress management, and hydration. myWanda then delivers daily tips, advice, and inspiration to help women stay on track to achieve these goals, thereby creating measureable improvements to their heart health and overall well-being.

 

Although heart disease is the number one killer of women in America, approximately 80 percent of cases are preventable through education and lifestyle changes. This is where myWanda comes in -- leveraging data science, applied medical research, and proven engagement methodologies to deliver support through a compelling, visually-driven mobile interface.

 

"myWanda is driving a revolution in healthcare that re-positions the patient to the very center of the care process," said Dr. Suzanne Steinbaum, renowned cardiologist and Medical Director of Wanda. "I'm thrilled to align my passion for educating women about heart health with myWanda's intelligent, impactful solution. Our goal is to empower women with the tools and knowledge they need to take control of their own health."

 

As Wanda's Medical Director, Dr. Steinbaum oversees the clinical content, consumer engagement, and clinical integrity. Dr. Steinbaum is a Fellow of the American College of Cardiology, and is the National Spokesperson for the Go Red for Women campaign. Experience and expertise has given Dr. Steinbaum a close view of the critical role that technology plays in managing women's healthcare; and she has seen in myWanda an innovative technology solution that stands out among health apps and demonstrates the potential to improve health, quality care, and convenience for women.

 

Wanda has long been dedicated to simplifying and improving the lives of individuals with chronic health conditions, blending predictive analytics and behavioral science to enrich the remote health and patient management experience. Through its research, Wanda identified the importance of proactively addressing the unique needs of women who are at risk of heart disease today. myWanda is the company's first consumer app, featuring a leading-class personalized communication strategy that makes it easy for women to receive support, education, and guidance.

 

"We're excited to bring a technology solution to market that can truly inform, motivate, and support women to take better care of their hearts, while continuing to advance our deep understanding of chronic conditions and the individual behaviors which affect them," said Wanda CEO Steve Curd, who is also former CIO of UnitedHealthCare and former COO of WebMD.

 

myWanda is already enjoying interest from large employers, especially those in healthcare, hoping to promote myWanda to their employees, members and communities. Such relationships with healthcare organizations are expected to open doors for the introduction and adoption of Wanda's core commercial solutions which are designed to prevent costly and disruptive hospital readmissions for those suffering with chronic diseases. The launch of myWanda expands Wanda's mission to proactively interact with people at various phases in the progression of disease -- from earliest risk identification and prevention through diagnosis and treatment. Most importantly, Wanda directly addresses the growing demand for science-driven solutions for post-acute and home-centered care.

"At Wanda, our approach has always been clear: how do we translate the most advanced technological capabilities into human-centered solutions," according to CCO Mark Heinemeyer. "The myWanda app truly embodies the vision of harnessing powerful technologies to improve people's lives."

 

To download myWanda in the iTunes App Store, please visit: https://itunes.apple.com/us/app/mywanda/id1125216315?ls=1&mt=8

 

For more information on Wanda, please visit:http://yourwanda.com/.

 

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

Stifel Nicolaus Europe Limited (NOMAD and broker)  Jonathan Senior / David Arch / Ben Maddison

Tel: +44 (0) 20 7710 7600

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

 

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found at www.yourwanda.com.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPPMBTMBTBTFF
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.